ATE452652T1 - Behandlung neurologischer und neuropsychiatrischer erkrankungen mit botulinumtoxin - Google Patents
Behandlung neurologischer und neuropsychiatrischer erkrankungen mit botulinumtoxinInfo
- Publication number
- ATE452652T1 ATE452652T1 AT08158950T AT08158950T ATE452652T1 AT E452652 T1 ATE452652 T1 AT E452652T1 AT 08158950 T AT08158950 T AT 08158950T AT 08158950 T AT08158950 T AT 08158950T AT E452652 T1 ATE452652 T1 AT E452652T1
- Authority
- AT
- Austria
- Prior art keywords
- neurological
- disorder
- botulinum toxin
- treatment
- neuropsychiatric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51536203P | 2003-10-29 | 2003-10-29 | |
US55615004P | 2004-03-24 | 2004-03-24 | |
US57495704P | 2004-05-26 | 2004-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE452652T1 true ATE452652T1 (de) | 2010-01-15 |
Family
ID=34923248
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04821587T ATE411813T1 (de) | 2003-10-29 | 2004-10-26 | Behandlungen mit botulinum toxin von neurologische und neuropsychiatrische krankheiten |
AT08158950T ATE452652T1 (de) | 2003-10-29 | 2004-10-26 | Behandlung neurologischer und neuropsychiatrischer erkrankungen mit botulinumtoxin |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04821587T ATE411813T1 (de) | 2003-10-29 | 2004-10-26 | Behandlungen mit botulinum toxin von neurologische und neuropsychiatrische krankheiten |
Country Status (14)
Country | Link |
---|---|
US (4) | US8734810B2 (de) |
EP (2) | EP1992357B1 (de) |
JP (2) | JP2007509953A (de) |
KR (2) | KR101234397B1 (de) |
CN (1) | CN100584379C (de) |
AT (2) | ATE411813T1 (de) |
AU (1) | AU2004316860B2 (de) |
BR (1) | BRPI0415558A (de) |
CA (1) | CA2544374C (de) |
DE (2) | DE602004017343D1 (de) |
DK (2) | DK1677823T3 (de) |
ES (2) | ES2314495T3 (de) |
MX (1) | MXPA06004609A (de) |
WO (1) | WO2005084705A1 (de) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US20020192239A1 (en) * | 2001-01-09 | 2002-12-19 | Borodic Gary E. | Use of botulinum toxin for the treatment of chronic facial pain |
US6921538B2 (en) * | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
US7758872B1 (en) | 2003-02-07 | 2010-07-20 | Eric Finzi | Method of treating depression |
MXPA05009424A (es) * | 2003-03-06 | 2006-02-10 | Botulinum Toxin Res Ass Inc | Tratamiento de chalazion cronico y hordeolum con la toxina botulinica. |
US20100266638A1 (en) | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US20050191321A1 (en) * | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
US9078892B2 (en) * | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US7897147B2 (en) * | 2004-10-20 | 2011-03-01 | Allergan, Inc. | Treatment of premenstrual disorders |
FR2879462B1 (fr) * | 2004-12-21 | 2008-12-26 | Sod Conseils Rech Applic | Utilisation de toxine botulique pour une insensibilisation locale prolongee |
US7655244B2 (en) * | 2005-02-01 | 2010-02-02 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
US8926991B2 (en) | 2005-06-14 | 2015-01-06 | Botulinum Toxin Research Associates, Inc. | Botulinum toxin and the treatment of primary disorders of mood and affect |
US20170319667A9 (en) * | 2005-06-14 | 2017-11-09 | Revance Therapeutics, Inc. | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect |
US20150258183A1 (en) * | 2006-06-07 | 2015-09-17 | Botulinum Toxin Research Associates, Inc. | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect |
EP2248534A1 (de) * | 2005-06-14 | 2010-11-10 | Botulinum Toxin Research Associates, Inc. | Botulinumtoxin und die Behandlung von primären Stimmungs- und Affektivenstörungen |
US20230390368A1 (en) * | 2005-06-27 | 2023-12-07 | Revance Therapeutics, Inc. | Methods of Treating Cervical Dystonia in a Subject Having Underlying Condition(s) |
US7910116B2 (en) * | 2005-08-24 | 2011-03-22 | Allergan, Inc. | Use of a botulinum toxin to improve gastric emptying and/or to treat GERD |
US20090324647A1 (en) * | 2005-10-11 | 2009-12-31 | Borodic Gary E | Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use |
EP2019143A1 (de) | 2007-07-23 | 2009-01-28 | Genethon | Gentherapie des ZNS mit peripher verabreichten AAV-Vektoren |
EP2058401A1 (de) | 2007-10-05 | 2009-05-13 | Genethon | Weitverbreitete Genverabreichung an Motorneuronen unter Verwendung einer peripheren Injektion von AAV-Vektoren |
US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
US8617571B2 (en) * | 2008-04-03 | 2013-12-31 | Allergan, Inc. | Suture line administration technique using botulinum toxin |
JPWO2010013495A1 (ja) * | 2008-07-31 | 2012-01-05 | 一般財団法人化学及血清療法研究所 | 高度精製ボツリヌス毒素治療剤を有効成分として含有する薬学的組成物およびその利用 |
EP2482838A4 (de) * | 2009-09-30 | 2013-04-10 | Toxcure Inc | Verwendung von botulinum-neurotoxin zur behandlung von substanzabhängigkeit |
US20120328701A1 (en) * | 2011-01-24 | 2012-12-27 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
US20120244188A1 (en) * | 2011-03-25 | 2012-09-27 | Allergan, Inc. | Treatment of Sensory Disturbance Disorders |
US20120251575A1 (en) * | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Involuntary Movement Disorders |
US20120251573A1 (en) * | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Neuroendocrine Disorders |
WO2012135304A1 (en) * | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Vagal nerve-based disorders |
US9764009B2 (en) * | 2011-06-13 | 2017-09-19 | Allergan, Inc. | Treatment of psychological trauma |
WO2013059735A1 (en) * | 2011-10-19 | 2013-04-25 | Mercator Medsystems, Inc. | Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation |
US8722060B2 (en) * | 2012-05-23 | 2014-05-13 | William J. Binder | Method of treating vertigo |
US20150231068A1 (en) | 2012-03-12 | 2015-08-20 | Miotox, Llc | Treatment of Migraine Headaches with Presynaptic Neurotoxin |
US20140056965A1 (en) * | 2012-08-24 | 2014-02-27 | Boston Scientific Neuromodulation Corporation | Method and system for treating depression or epilepsy |
EP2919807B1 (de) | 2012-11-16 | 2018-07-11 | Finzi, Eric | Behandlung von posttraumatischen stresszuständen mit botulinumtoxin a |
US10149893B2 (en) | 2013-09-24 | 2018-12-11 | Allergan, Inc. | Methods for modifying progression of osteoarthritis |
EP3068423A1 (de) | 2013-11-12 | 2016-09-21 | Finzi, Eric | Behandlung von sozialen angststörungen, zwangsneurosen und panikstörungen mit botulinumtoxin |
KR101677710B1 (ko) * | 2014-06-30 | 2016-11-21 | (주)메디톡스 | 보툴리눔 독소를 유효성분으로 포함하는 골관절염 치료용 약제학적 조성물 및 그를 이용한 골관절염 치료 방법 |
EP3325001A1 (de) * | 2015-07-24 | 2018-05-30 | Medizinische Hochschule Hannover | Neurotoxin zur verwendung bei der behandlung von persönlichkeitsstörungen |
EP3120867A1 (de) | 2015-07-24 | 2017-01-25 | Medizinische Hochschule Hannover | Neurotoxin zur verwendung in der behandlung von persönlichkeitsstörungen |
JP6775299B2 (ja) * | 2015-08-21 | 2020-10-28 | 日本メジフィジックス株式会社 | 脳ファントム |
SG11201804840SA (en) * | 2015-12-11 | 2018-07-30 | Revance Therapeutics Inc | Botulinum toxin for primary disorders of mood and affect using neurotransmitter |
KR20240023684A (ko) * | 2016-09-13 | 2024-02-22 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
MX2019011196A (es) | 2017-03-22 | 2020-01-20 | Bonti Inc | Neurotoxinas botulinas para uso en terapia. |
AU2018237205A1 (en) * | 2017-03-22 | 2019-10-31 | Bonti, Inc. | Botulinum neurotoxins for treating traumatic injuries |
AU2019299676A1 (en) | 2018-07-05 | 2021-01-28 | Allergan Pharmaceuticals International Limited | Combination therapy with CGRP antagonists and Clostridial derivatives |
KR20220029740A (ko) * | 2019-07-05 | 2022-03-08 | 알러간, 인코포레이티드 | 발작을 치료하고 그의 진행을 억제하는 방법 |
WO2021005494A1 (en) | 2019-07-05 | 2021-01-14 | Allergan Pharmaceuticals International Limited | Cgrp antagonists and clostridial derivatives for the treatment of neuropsychiatric and neurological disorders |
US20210130445A1 (en) | 2019-07-05 | 2021-05-06 | Allergan Pharmaceuticals International Limited | CGRP Antagonists and Botulinum Toxins for the Treatment of Inflammatory and Neurologic Disorders |
WO2021005497A1 (en) | 2019-07-05 | 2021-01-14 | Allergan Pharmaceuticals International Limited | Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders |
US11090371B1 (en) | 2019-10-18 | 2021-08-17 | Penland Foundation | Treatment of cirrhosis using botulinum toxin |
WO2021077055A1 (en) * | 2019-10-18 | 2021-04-22 | Penland Foundation | Botulinum toxin for use in treatment |
US11241479B2 (en) | 2019-10-18 | 2022-02-08 | Penland Foundation | Treatment methods using botulinum toxins |
US10987411B1 (en) | 2019-10-18 | 2021-04-27 | Penland Foundation | Treatment of chronic obstructive pulmonary disease using botulinum toxin |
US10960061B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of amyotrophic lateral sclerosis using botulinum toxin |
US10960060B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of cardiac arrhythmia using botulinum toxin |
US10973873B1 (en) | 2019-10-18 | 2021-04-13 | Penland Foundation | Treatment of asthma using botulinum toxin |
US10722552B1 (en) * | 2019-10-18 | 2020-07-28 | Penland Foundation | Treatment of autism using botulinum toxins |
US10967052B1 (en) | 2019-10-18 | 2021-04-06 | Penland Foundation | Treatment of dyslexia using botulinum toxin |
US11925677B2 (en) | 2021-07-12 | 2024-03-12 | Penland Foundation | Treatment of diabetes and chronic pancreatitis using botulinum toxin |
WO2021247890A1 (en) * | 2020-06-03 | 2021-12-09 | Miotox, Llc | Zonal and targeted methods and uses for treating a migraine disorder |
WO2023287729A1 (en) | 2021-07-12 | 2023-01-19 | Penland Foundation | Treatment of acute and chronic kidney disease |
WO2023201080A1 (en) * | 2022-04-15 | 2023-10-19 | AEON Biopharma, Inc. | Neurotoxin compositions for use in modulating stellate ganglion activity |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US157926A (en) | 1874-12-22 | Improvement in belt clasps or buckles | ||
US286127A (en) | 1883-10-02 | Automatic car brake | ||
US234727A (en) | 1880-11-23 | Car-coupling | ||
US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
GB9120306D0 (en) | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US5427291A (en) | 1993-09-21 | 1995-06-27 | Smith; David S. | Ski carrier and method employing same |
DE69435270D1 (de) | 1993-12-28 | 2010-04-01 | Allergan Inc | Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln |
US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
ES2238969T3 (es) | 1994-05-09 | 2005-09-16 | William J. Binder | Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas. |
US5670484A (en) | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
GB9524807D0 (en) | 1995-12-05 | 1996-02-07 | Smithkline Beecham Plc | Novel compounds |
US6094598A (en) | 1996-04-25 | 2000-07-25 | Medtronics, Inc. | Method of treating movement disorders by brain stimulation and drug infusion |
US5713923A (en) | 1996-05-13 | 1998-02-03 | Medtronic, Inc. | Techniques for treating epilepsy by brain stimulation and drug infusion |
US6272370B1 (en) | 1998-08-07 | 2001-08-07 | The Regents Of University Of Minnesota | MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging |
ES2385130T3 (es) | 1997-07-15 | 2012-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Uso de terapia con neurotoxinas para el tratamiento de enfermedades urológicas y de enfermedades relacionadas |
US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
TW574036B (en) | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
CN1324246A (zh) | 1998-10-27 | 2001-11-28 | 梅约医学教育与研究基金会 | 增加伤口愈合的方法 |
US6358917B1 (en) | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
US6265379B1 (en) | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
US6143306A (en) | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
US6358513B1 (en) | 2000-02-15 | 2002-03-19 | Allergan Sales, Inc. | Method for treating Hashimoto's thyroiditis |
US6328977B1 (en) | 2000-02-22 | 2001-12-11 | Allergan Sales, Inc. | Method for treating hyperparathyroidism |
US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US6299893B1 (en) | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US6306403B1 (en) | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
US20020192239A1 (en) * | 2001-01-09 | 2002-12-19 | Borodic Gary E. | Use of botulinum toxin for the treatment of chronic facial pain |
AU2002355730B2 (en) | 2001-07-27 | 2007-09-13 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Botulinum toxin in the treatment or prevention of acne |
US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
DE10150415A1 (de) | 2001-10-11 | 2003-05-15 | Andres O Ceballos-Baumann | Arzneimittel zur Prophylaxe und Therapie von Depressionen |
US20030224019A1 (en) | 2002-03-01 | 2003-12-04 | O'brien Christopher | Methods of treating nerve entrapment syndromes |
US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
US6762687B2 (en) | 2002-06-20 | 2004-07-13 | David Perlman | Biofeedback device for treating obsessive compulsive spectrum disorders (OCSDs) |
US20040138097A1 (en) * | 2002-11-01 | 2004-07-15 | Bahman Guyuron | Method and treatment for treating and preventing pain associated with compression of a nerve |
IL154318A (en) | 2003-02-06 | 2010-05-31 | Sarah Herzog Memorial Hospital | Pharmaceutical compositions for the treatment of movement disorders |
MXPA05009425A (es) | 2003-03-06 | 2006-02-10 | Botulinum Toxin Res Ass Inc | Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica. |
US7393537B2 (en) | 2003-04-25 | 2008-07-01 | Allergan, Inc. | Botulinum toxin for treatment of obsessive compulsive finger biting disorder |
US6838434B2 (en) | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
US7655244B2 (en) | 2005-02-01 | 2010-02-02 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
US7749515B2 (en) | 2005-02-01 | 2010-07-06 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
US8105611B2 (en) | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
-
2004
- 2004-10-12 US US10/964,898 patent/US8734810B2/en not_active Expired - Fee Related
- 2004-10-26 DK DK04821587T patent/DK1677823T3/da active
- 2004-10-26 ES ES04821587T patent/ES2314495T3/es active Active
- 2004-10-26 KR KR1020117016938A patent/KR101234397B1/ko active IP Right Grant
- 2004-10-26 MX MXPA06004609A patent/MXPA06004609A/es active IP Right Grant
- 2004-10-26 AT AT04821587T patent/ATE411813T1/de not_active IP Right Cessation
- 2004-10-26 EP EP08158950A patent/EP1992357B1/de not_active Not-in-force
- 2004-10-26 CA CA2544374A patent/CA2544374C/en not_active Expired - Fee Related
- 2004-10-26 ES ES08158950T patent/ES2336389T3/es active Active
- 2004-10-26 DE DE602004017343T patent/DE602004017343D1/de active Active
- 2004-10-26 CN CN200480032249A patent/CN100584379C/zh not_active Expired - Fee Related
- 2004-10-26 EP EP04821587A patent/EP1677823B1/de not_active Not-in-force
- 2004-10-26 DK DK08158950.9T patent/DK1992357T3/da active
- 2004-10-26 BR BRPI0415558-0A patent/BRPI0415558A/pt not_active Application Discontinuation
- 2004-10-26 AU AU2004316860A patent/AU2004316860B2/en not_active Ceased
- 2004-10-26 KR KR1020067008158A patent/KR101095725B1/ko active IP Right Grant
- 2004-10-26 WO PCT/US2004/035592 patent/WO2005084705A1/en active Application Filing
- 2004-10-26 AT AT08158950T patent/ATE452652T1/de not_active IP Right Cessation
- 2004-10-26 JP JP2006538205A patent/JP2007509953A/ja active Pending
- 2004-10-26 DE DE602004024836T patent/DE602004024836D1/de active Active
-
2012
- 2012-04-10 JP JP2012089468A patent/JP2012140462A/ja active Pending
-
2014
- 2014-04-08 US US14/247,469 patent/US20140205590A1/en not_active Abandoned
-
2017
- 2017-03-02 US US15/447,770 patent/US10064921B2/en not_active Expired - Fee Related
-
2018
- 2018-08-31 US US16/119,252 patent/US20180369348A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN100584379C (zh) | 2010-01-27 |
JP2012140462A (ja) | 2012-07-26 |
US20180369348A1 (en) | 2018-12-27 |
ES2314495T3 (es) | 2009-03-16 |
US20140205590A1 (en) | 2014-07-24 |
CA2544374C (en) | 2012-07-31 |
DK1677823T3 (da) | 2009-02-16 |
CN1874786A (zh) | 2006-12-06 |
MXPA06004609A (es) | 2006-06-27 |
US20050147626A1 (en) | 2005-07-07 |
AU2004316860A1 (en) | 2005-09-15 |
US10064921B2 (en) | 2018-09-04 |
KR20110097973A (ko) | 2011-08-31 |
CA2544374A1 (en) | 2005-09-15 |
JP2007509953A (ja) | 2007-04-19 |
WO2005084705A1 (en) | 2005-09-15 |
ATE411813T1 (de) | 2008-11-15 |
KR101234397B1 (ko) | 2013-02-18 |
KR101095725B1 (ko) | 2011-12-21 |
DE602004017343D1 (de) | 2008-12-04 |
DK1992357T3 (da) | 2010-04-12 |
EP1677823B1 (de) | 2008-10-22 |
AU2004316860B2 (en) | 2009-12-03 |
BRPI0415558A (pt) | 2006-12-26 |
US8734810B2 (en) | 2014-05-27 |
EP1992357A1 (de) | 2008-11-19 |
US20170173123A1 (en) | 2017-06-22 |
EP1677823A1 (de) | 2006-07-12 |
DE602004024836D1 (de) | 2010-02-04 |
ES2336389T3 (es) | 2010-04-12 |
EP1992357B1 (de) | 2009-12-23 |
KR20060115370A (ko) | 2006-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE452652T1 (de) | Behandlung neurologischer und neuropsychiatrischer erkrankungen mit botulinumtoxin | |
WO2008039898A3 (en) | Methods for the treatment of a traumatic central nervous system injury | |
IL267381A (en) | A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders | |
MX337511B (es) | Medicamentos y metodos para tratar cefaleas. | |
WO2006102596A3 (en) | Dosage regimen for the treatment of a traumatic brain injury with progesterone | |
ATE480255T1 (de) | Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen | |
IL197890A (en) | Arylvinylchloroalkylan compounds and their preparation methods and uses | |
IL171607A (en) | Use of botulinum toxin for the treatment of sinusitis-induced headaches | |
DE60323628D1 (de) | Intrakraniale behandlung neuropsychiatrischer krankheiten mit clostridium neurotoxinen wie botulinus toxin | |
DK2282766T3 (da) | Suturlinie-indgivelsesteknik med anvendelse af botulinumtoksiner | |
ATE451368T1 (de) | Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems | |
DE60333857D1 (de) | Oxytocin zur Behandlung von Autismus und Asperger-Syndrom | |
DE602006002135D1 (de) | Verwendung von Naloxon zur Behandlung von Essstörungen | |
WO2002089805A3 (en) | Use of regularly scheduled high dose intravenous methotrexate therapy | |
TW200510437A (en) | Phosphinane compound with immunomodulating activity | |
RU2006147345A (ru) | Способ лечения заболеваний, травм перефирической нервной системы, их последствий и последствий нарушения спинального мозгового кровообращения и спинальных травм | |
ATE428470T1 (de) | Heilmittel zur behandlung von erkrankungen des sehnervs | |
WO2023107552A3 (en) | Purines and methods of their use | |
WO2003103699A8 (en) | USE OF RAMOPLANIN TO TREAT DISORDERS ASSOCIATED WITH THE TAKING OF ANTIBIOTICS | |
ATE394122T1 (de) | Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen | |
SE0004455D0 (sv) | Method for neuron regeneration in the central nervous system | |
WO2006078588A3 (en) | Improved methods for treating headache | |
WO2005120489A3 (en) | Treatment of central nervous system disorders or injuries with d-methionine | |
UA2972U (uk) | Спосіб лікування початкових проявів розсіяного склерозу |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |